These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 26209311)

  • 1. In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa.
    Walsh CC; McIntosh MP; Peleg AY; Kirkpatrick CM; Bergen PJ
    J Antimicrob Chemother; 2015 Nov; 70(11):3042-50. PubMed ID: 26209311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.
    Walsh CC; Landersdorfer CB; McIntosh MP; Peleg AY; Hirsch EB; Kirkpatrick CM; Bergen PJ
    J Antimicrob Chemother; 2016 Aug; 71(8):2218-29. PubMed ID: 27118778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase.
    Albiero J; Mazucheli J; Barros JPDR; Szczerepa MMDA; Nishiyama SAB; Carrara-Marroni FE; Sy S; Fidler M; Sy SKB; Tognim MCB
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions.
    McCaughey G; McKevitt M; Elborn JS; Tunney MM
    J Cyst Fibros; 2012 May; 11(3):163-72. PubMed ID: 22138067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant Pseudomas aeruginosa.
    Di X; Wang R; Liu B; Zhang X; Ni W; Wang J; Liang B; Cai Y; Liu Y
    J Antibiot (Tokyo); 2015 Sep; 68(9):551-5. PubMed ID: 25805069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies.
    Falagas ME; Kastoris AC; Karageorgopoulos DE; Rafailidis PI
    Int J Antimicrob Agents; 2009 Aug; 34(2):111-20. PubMed ID: 19403273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model.
    Lora-Tamayo J; Murillo O; Bergen PJ; Nation RL; Poudyal A; Luo X; Yu HY; Ariza J; Li J
    J Antimicrob Chemother; 2014 Sep; 69(9):2434-42. PubMed ID: 24833752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shape does matter: short high-concentration exposure minimizes resistance emergence for fluoroquinolones in Pseudomonas aeruginosa.
    Rees VE; Bulitta JB; Nation RL; Tsuji BT; Sörgel F; Landersdorfer CB
    J Antimicrob Chemother; 2015 Mar; 70(3):818-26. PubMed ID: 25381167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.
    Li J; Turnidge J; Milne R; Nation RL; Coulthard K
    Antimicrob Agents Chemother; 2001 Mar; 45(3):781-5. PubMed ID: 11181360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.
    Díez-Aguilar M; Morosini MI; Köksal E; Oliver A; Ekkelenkamp M; Cantón R
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084746
    [No Abstract]   [Full Text] [Related]  

  • 11. Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance.
    Ly NS; Bulitta JB; Rao GG; Landersdorfer CB; Holden PN; Forrest A; Bergen PJ; Nation RL; Li J; Tsuji BT
    J Antimicrob Chemother; 2015 May; 70(5):1434-42. PubMed ID: 25712313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae.
    Poudyal A; Howden BP; Bell JM; Gao W; Owen RJ; Turnidge JD; Nation RL; Li J
    J Antimicrob Chemother; 2008 Dec; 62(6):1311-8. PubMed ID: 18922815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic activity of fosfomycin simulating urinary concentrations achieved after a single 3-g oral dose versus Escherichia coli using an in vitro model.
    Zhanel GG; Parkinson K; Higgins S; Denisuik A; Adam H; Pitout J; Noreddin A; Karlowsky JA
    Diagn Microbiol Infect Dis; 2017 Jul; 88(3):271-275. PubMed ID: 28483306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation.
    Asuphon O; Montakantikul P; Houngsaitong J; Kiratisin P; Sonthisombat P
    Int J Infect Dis; 2016 Sep; 50():23-9. PubMed ID: 27418581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of the Dynamically Linked Indices of Fosfomycin for Pseudomonas aeruginosa in the Hollow Fiber Infection Model.
    Louie A; Maynard M; Duncanson B; Nole J; Vicchiarelli M; Drusano GL
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29581114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elucidation of the pharmacokinetic/pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro model.
    Bilal H; Peleg AY; McIntosh MP; Styles IK; Hirsch EB; Landersdorfer CB; Bergen PJ
    J Antimicrob Chemother; 2018 Jun; 73(6):1570-1578. PubMed ID: 29506207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rhesus θ-defensin-1 (RTD-1) exhibits in vitro and in vivo activity against cystic fibrosis strains of Pseudomonas aeruginosa.
    Beringer PM; Bensman TJ; Ho H; Agnello M; Denovel N; Nguyen A; Wong-Beringer A; She R; Tran DQ; Moskowitz SM; Selsted ME
    J Antimicrob Chemother; 2016 Jan; 71(1):181-8. PubMed ID: 26433781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of erythromycin and fosfomycin on Pseudomonas aeruginosa biofilm in vitro].
    Xu Z; Liu F; Wang X
    Zhonghua Jie He He Hu Xi Za Zhi; 2001 Jun; 24(6):342-4. PubMed ID: 11802985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy.
    Sime FB; Johnson A; Whalley S; Santoyo-Castelazo A; Montgomery AB; Walters KA; Lipman J; Hope WW; Roberts JA
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of single and multiple oral doses of fosfomycin against Pseudomonas aeruginosa urinary tract infections in a dynamic in vitro bladder infection model.
    Abbott IJ; van Gorp E; Wijma RA; Dekker J; Croughs PD; Meletiadis J; Mouton JW; Peleg AY
    J Antimicrob Chemother; 2020 Jul; 75(7):1879-1888. PubMed ID: 32361749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.